ResMed Stock Is Estimated To Be Modestly Overvalued
The stock of ResMed (NYSE:RMD, 30-year Financials) is believed to be modestly overvalued, according to GuruFocus Value calculation.
Because Resmed Medical Devices Gurufocus High Quality Low Capex Gurufocus Value Financial Strength Business Growth
Source: yahoo.com